Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

August 23, 2023

a230817_00.png

a230817_01.png

Previous: VOLUNTARY ANNOUNCEMENT - STRATEGIC COLLABORATION AGREEMENTS IN THE FIELD OF ARTIFICIAL INTELLIGENCE (AI) IN INNOVATIVE DRUG RESEARCH AND DEVELOPMENT

Next: CSPC Products Certified by Columbia's INVIMA

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat